Clinical Study Of Yiqi Fuzheng Mixture Combined With EGFR-TKI In The Treatment Of Non-small Cell Lung Cancer (Qi And Yin Deficiency Type)

Objective:The effectiveness and safety of the combination of Yiqi Fuzheng Mixture and EGFR-TKI in the treatment of advanced non-small cell lung cancer were evaluated by comparison.Methods:Randomly divide 60 patients who meet the criteria into two groups with 30 cases in each group.The treatment group was treated with EGFR-TKI alone,and the control group was treated with Yiqi Fuzheng Mixture on this basis.To observe and compare the short-term efficacy,progression-free survival,karnofsky score,TCM syndrome classification,adverse reactions,safety indicators,and expression levels of tumor markers before and after treatment between the two groups.After the end of clinical observation and data statistics,use spss 26.0 software for analysis.Results:(1)Baseline data: Two groups in smoking history,histological type,clinical stage,gender,age,targeted drug treatment before KPS,TCM level terms,the comparative analysis of baseline,no significant difference(P>0.05),between the two groups Comparable.(2)Short-term efficacy:The ORR and DCR(ORR 60.0%;DCR 93.3%)of the treatment group were higher than those of the control group(ORR52.3%;ORR 90.0%).After teting,there was no significant difference(P>0.05).(3)TCM syndrome score: Two groups of patients after treatment,shortness of breath,cough and sputum before the scores were reduced.(P<0.05).The treatment group can improve the patients’ shortness of breath,cough and sputum,and can also improve the patients’ loss of appetite,fatigue,fatigue,upset,insomnia,sputum blood,nausea and vomiting,chest tightness,the difference is statistically significant(P<0.05).In the control group,while improving shortness of breath,cough and sputum,it also aggravated nausea,vomiting,oropharyngeal drying,the difference was statistically significant(P<0.05).Before and after treatment of nausea,vomiting,oropharyngeal Sjogren no significant difference(P>0.05).(P>0.05).TCM treatment group improve the total efficiency(73.33%)than the control group(46.76%),and the difference is statistically significant.(P<0.05).(4)PFS:The treatment group was significantly longer than the control group,and the difference was statistically significant(P<0.05).(5)KPS score:Treatment group before and after treatmen,statistically significant differencest(P <0.05);The control group before and after treatment(P> 0.05),not statistically significant(P> 0.05).Effect KPS scores treatment group than the control group,the difference was statistically significant,P = 0.038 <0.05.(6)Tumor markers:After treatment,the CEA level of the treatment group decreased more significantly than that of the control group,and the difference between the two groups was significant(P<0.05).There was no significant difference between the two groups before and after CA125 and CYFRA211 treatment(P>0.05).(7)Toxic side effects:The incidence of rash in the control group(73.33%)was significantly higher than that in the treatment group(44.33%),and the difference was statistically significant(P= 0.014 <0.05).The incidence of diarrhea was similar in the two groups,and the difference was not statistically significant(P>0.05).(8)Safety evaluation:After treatment,the blood routine,liver function,kidney function of the two gruops of patients were not significantly different from those before treatment(P>0.05).Conclusion:Yiqi Fuzheng Mixture combined with EGFR-TKI in the treatment of patients with advanced NSCLC has good safety.Not only can it better improve the quality of life and improve the clinical symptoms of lung cancer patients,it can also effectively reduce the side effects caused by targeted drugs,prolong the progression-free survival period of patients,and delay the occurrence of drug resistance.